Sean M. Bagshaw
Dr. Bagshaw is a Professor and Chair, of the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, at the University of Alberta. He trained at the University of Calgary (Internal Medicine, Critical Care Medicine, Master of Science Epidemiology) and the Austin Hospital (Critical Care Nephrology) in Melbourne, Australia. He also serves as the Scientific Director of the Alberta Health Services Critical Care Strategic Clinical Network.
Dr. Bagshaw is supported by a Canada Research Chair in Critical Care Outcomes and Systems Evaluation. He has research expertise in clinical epidemiology, clinical trials, and health services research. His research focuses on acute kidney injury, vulnerable populations (e.g., elderly, frail), ICU organization and capacity. He is co-Chair of the multi-national STARRT-AKI trial.
Recent work
Bowker S, Williams K, Volk A, Auger L, Lafontaine A. Dumont P, Wingert A, Davis A, Bialy L, Wright E, Oster RT, Bagshaw SM. Incidence and outcomes of critical illness in Indigenous Peoples: A Systematic Review and Meta-Analysis. Crit Care 2023; 27(1):285 (doi: 10.1186/s13054-023-04570-y).
Zampieri FG, Bagshaw SM, Semler MW. Fluid Therapy for Critically Ill Adults With Sepsis: A Review. JAMA. 2023;329(22):1967-1980 (doi: 10.1001/jama.2023.7560).
Bagshaw SM, Abbott A, Beesoon S, Bowker SL, Zuege DJ, Thanh NX. A population-based assessment of avoidable hospitalizations and resource use of non-vaccinated patients with COVID-19. Can J Public Health. 2023:1-8 (doi: 10.17269/s41997-023-00777-2).
Bagshaw SM, Neto AS, Smith O, Weir M, Qiu H, Du B, Wang AY, Gallagher M, Bellomo R, Wald R; STARRT-AKI Investigators. Impact of renal-replacement therapy strategies on outcomes for patients with chronic kidney disease: a secondary analysis of the STARRT-AKI trial. Intensive Care Med. 2022: Epub: Nov 4 (doi: 10.1007/s00134-022-06912-w).
Bagshaw SM, Zuege DJ, Stelfox HT, Opgenorth D, Wasylak T, Fraser N, Nguyen TX; Critical Care Strategic Clinical Network, Alberta Health Services, Alberta, Canada. Association Between Pandemic Coronavirus Disease 2019 Public Health Measures and Reduction in Critical Care Utilization Across ICUs in Alberta, Canada. Crit Care Med 2021: ePub Sep 8 (doi: 10.1097/CCM.0000000000005275).
Bagshaw SM, Al-Khafaji A, Artigas A, Davison D, Haase M, Lissauer M, Zacharowski K, Chawla LS, Kwan T, Kampf JP, McPherson P, Kellum JA. External validation of urinary C-C motif chemokine ligand 14 (CCL14) for prediction of persistent acute kidney injury. Crit Care 2021;25(1):185. doi: 10.1186/s13054-021-03618-1).
Wald R, Bagshaw SM; STARRT-AKI Investigators. Integration of Equipoise into Eligibility Criteria in the STARRT-AKI Trial. Am J Respir Crit Care Med 2021: ePub May 3 (doi: 10.1164/rccm.202009-3425LE).
Bagshaw SM, Tran DT, Opgenorth D, Wang X, Zuege DJ, Ingolfsson A, Stelfox HT, Thanh NX. Assessment of costs of avoidable delays in Intensive Care Unit Discharge. JAMA Netw Open 2020; 3(8):e2013913 (PMID: 32822492).
The STARRT-AKI Investigators. Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury. New Engl J Med 2020; 383(3):240-251 (PMID: 32668114).
PEPTIC Investigators; Young P, Bagshaw SM et al. Effect of Stress Ulcer Prophylaxis With Proton Pump Inhibitors vs Histamine-2 Receptor Blockers on In-Hospital Mortality Among ICU Patients Receiving Invasive Mechanical Ventilation: The PEPTIC Randomized Clinical Trial. JAMA 2020;323(7):616-626 (doi: 10.1001/jama.2019.22190).